Skip to main content

A LA CAZA DE GENES ESQUIVOS: ELA, EPILEPSIA Y PSP

SAF2014-59469-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

PM20D1 is a quantitative trait locus associated with Alzheimer's disease

  • Sánchez-Mut, José V.
  • Heyn, Holger
  • Silva, Bianca Ambrogina
  • Dixsaut, Lucie
  • García-Esparcia, Paula
  • Vidal, Enrique
  • Sayols, Sergi
  • Glauser, Liliane
  • Monteagudo-Sánchez, Ana
  • Pérez-Tur, Jordi
  • Ferrer, Isidro
  • Monk, David
  • Schneider, Bernard
  • Esteller, Manel
  • Gräff, Johannes
6 páginas, 3 figuras. En material suplementario 3 tablas, 7 figuras., The chances to develop Alzheimer’s disease (AD) result from a combination of genetic and non-genetic risk factors1, the latter likely mediated by epigenetic mechanisms2. In the past, genome-wide association studies (GWAS) have identified an important number of risk loci associated with AD pathology3, but a causal relationship thereof remains difficult to establish. In contrast, locus-specific or epigenome-wide association studies (EWAS) have revealed site-specific epigenetic alterations and thereby provide mechanistic insights for a particular risk gene, but often lack the statistical power of GWAS4. Here, combining both approaches, we report a hitherto unidentified association of the Peptidase M20 domain-containing protein 1 (PM20D1) with AD. We find that PM20D1 is a methylation/expression quantitative trait locus (mQTL/eQTL) coupled to an AD-risk associated haplotype, which displays enhancer-like characteristics and contacts the PM20D1 promoter via a haplotype-dependent, CTCF-mediated chromatin loop. Furthermore, PM20D1 is increased following AD-related neurotoxic insults, at symptomatic stages in the APP/PS1 mouse model of AD and in human AD patients, who are carriers of the non-risk haplotype. Importantly, genetically increasing and decreasing the expression of PM20D1 reduces and aggravates AD-related pathologies, respectively. These findings suggest that in a particular genetic background, PM20D1 contributes to neuroprotection against AD., The work in the laboratory of J.G. is supported by the SYNAPSIS Foundation, the Béatrice Ederer-Weber Stiftung, the Floshield Foundation and the Alzheimer’s Association (grant no. NIRG-15-363964). The laboratory of D.M. is supported by the Foundation Jérôme Lejeune, Spanish Ministerio de Educación y Competitividad (grant no. BFU2014-53093). The laboratory of J.P.-T. is supported by the Spanish Ministerio de Economía, Industria y Competitividad and the FEDER programme from the EU (grant no. SAF2014-59469-R) and the CIBERNED. J.V.S.-M. is supported by a SYNAPSIS Foundation Fellowship for Advanced PostDocs and the Heidi Seiler-Stiftung foundation. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). B.A.S. is an EMBO long-term fellow (ALTF 1605-2014, Marie Curie Actions, LTFCOFUND2013, GA-2013-609409). A.M.-S. is a recipient of a FPI PhD studentship from MINECO. M.E. is an ICREA Research Professor. J.G. is an MQ fellow and a NARSAD Independent Investigator., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clinical profile of motor neuron disease patients with lower urinary tract symptoms and neurogenic bladder

  • Vázquez-Costa, Juan Francisco
  • Arlandis, Salvador
  • Hervás, David
  • Martínez-Cuenca, Esther
  • Cardona, Fernando
  • Pérez-Tur, Jordi
  • Broseta, Enrique
  • Sevilla, Teresa
7 págs, 1 figura, 4 tablas. Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.jns.2017.04.053., Introduction: Lower urinary tract symptoms (LUTS) are frequent in motor neuron disease (MND) patients, but clinical factors related to them are unknown. We describe differences in LUTS among MND phenotypes and their relationship with other clinical characteristics, including prognosis. Methods: For this study, we collected clinical data of a previously published cohort of patients diagnosed with classical amyotrophic lateral sclerosis (cALS), progressive muscular atrophy (PMA) or primary lateral sclerosis (PLS) with and without LUTS. Familial history was recorded and the C9ORF72 expansion was analysed in the entire cohort. Patients were followed-up for survival until August 2016. Results: Fifty-five ALS patients (37 cALS, 10 PMA and 8 PLS) were recruited. Twenty-four reported LUTS and neurogenic bladder (NB) could be demonstrated in nine of them. LUTS were not influenced by age, phenotype, disability, cognitive or behavioural impairment, or disease progression, but female sex appeared to be a protective factor (OR=0.39, p=0.06). Neither family history nor the C9ORF72 expansion was linked to LUTS or NB. In the multivariate analysis, patients reporting LUTS early in the disease course tended to show poorer survival. Conclusions: In this study, LUTS appear to be more frequent in male MND patients, but are not related to age, clinical or genetic characteristics. When reported early, LUTS could be a sign of rapid disease spread and poor prognosis. Further prospective longitudinal and neuroimaging studies are warranted to confirm this hypothesis., This work was supported the Instituto de Investigación Sanitaria La Fe (2013/0332, PI Vázquez/Sevilla); by the Instituto de Salud Carlos III (ISCIII, PI12/0946, PI Sevilla) and the Ministerio de Economía, Industria y Competitividad (SAF2014-59469-R, PI: Pérez-Tur). The Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and the Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED) are initiatives from the ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clinical and neuroimaging characterization of two C9orf72-positive siblings with amyotrophic lateral sclerosis and schizophrenia

  • Vázquez-Costa, Juan F
  • Beltrán, Eva
  • Sopena, Pablo
  • Sabater, Ana
  • Cardona, Fernando
  • Vílchez, Juan J.
  • Pérez-Tur, Jordi
  • Sevilla, Teresa
4 páginas, he research leading to these results has received funding from Instituto de Investigación Sanitaria La Fe (2013/0332, PI JFVC/ TS), from Instituto de Salud Carlos III (ISCIII, PI12/0946, PI TS) and from Ministerio de Economía y Competitividad (SAF2014-59469-R; PI: JPT). The Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and the Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED) are initiatives from the ISCIII., Peer reviewed